27.02
-2.56 (-8.65%)
| Previous Close | 29.58 |
| Open | 26.84 |
| Volume | 12,507,897 |
| Avg. Volume (3M) | 12,034,033 |
| Market Cap | 37,270,011,904 |
| Price / Earnings (Forward) | 588.24 |
| Price / Sales | 12.30 |
| Price / Book | 4.67 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | -59.61% |
| Operating Margin (TTM) | -53.93% |
| Diluted EPS (TTM) | -1.42 |
| Quarterly Revenue Growth (YOY) | 31.50% |
| Total Debt/Equity (MRQ) | 49.07% |
| Current Ratio (MRQ) | 1.39 |
| Operating Cash Flow (TTM) | -1.08 B |
| Levered Free Cash Flow (TTM) | -261.82 M |
| Return on Assets (TTM) | -7.13% |
| Return on Equity (TTM) | -21.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | JUNSHI BIO | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | -1.63 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| JUNSHI BIO | 37 B | - | - | 4.67 |
| SINO BIOPHARM | 148 B | 1.15% | 34.46 | 3.82 |
| WUXI BIO | 146 B | - | 33.57 | 3.49 |
| INNOVENT BIO | 167 B | - | 132.16 | 10.62 |
| AKESO | 138 B | - | - | 18.31 |
| PHARMARON | 65 B | 0.92% | 32.78 | 3.36 |
|
Shanghai Junshi Biosciences Co Ltd is mainly engaged in innovation-driven biopharmaceutical business. The company's main products include teriprizumab injection, Etesevimab, adalimumab injection, and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases, and infectious diseases. The group’s operations are mainly located in the PRC and the United States of America. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Core |
| % Held by Insiders | 19.28% |
| % Held by Institutions | 16.09% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |